BioPharmSignal logoBioPharmSignal

Biotech News

Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026

Tempest Therapeutics (TPST)Tempest TherapeuticsPartnership

Cincinnati Children’s Applied Gene and Cell Therapy Center selected to conduct tech transfer, development and IND-enabling manufacturing All activities other than long-term stability testing planned to be complete in Q3 2026 to support potential IND filing in Q4 2026 Selection of tech transfer

Related news

TPSTTempest Therapeutics2026-07-21 11:00 EST

Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T

TPSTTempest Therapeutics2026-07-15 11:00 EST

Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026

NRIXNurix Therapeutics2026-06-08 05:00 EST

Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

NRIXNurix Therapeutics2026-07-21 20:01 EST

Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

BMYBMYBristol-Myers Squibb Company2026-06-08 10:59 EST

Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease

RVMDRevolution Medicines2026-08-10 10:01 EST

Revolution Medicines and BeOne Medicines Announce Clinical Development and Regional Commercialization Collaboration

BMYBMYBristol-Myers Squibb Company2026-07-20 10:59 EST

Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA

IDYAIDEAYA Biosciences2026-08-19 10:00 EST

IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer

MGNXMacroGenics2026-08-11 20:05 EST

MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program

CHRSCoherus BioSciences, Inc.2026-06-23 18:00 EST

Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)

View all latest news

Tempest Therapeutics

In Vivo CAR T Company Tempest Therapeutics develops next-generation CAR T therapies for autoimmune diseases and cancer. Its platform is designed to generate therapeutic CAR T cells directly inside the body using targeted mRNA and lipid nanoparticles. CD7-Targeted Delivery Tempest's proprietary delivery system targets CD7-positive T cells...

Recent company news

TPSTTempest Therapeutics2026-08-13 20:26 EST

Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update

TPSTTempest Therapeutics2026-07-21 11:00 EST

Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T

TPSTTempest Therapeutics2026-07-15 11:00 EST

Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026

TPSTTempest Therapeutics2026-06-04 20:37 EST

Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors

TPSTTempest Therapeutics2026-05-29 12:00 EST

Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds

Stock data

Close
1.04 USD
Market cap
19.4M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States